EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, cilt.109, ss.402-411, 2017 (SCI-Expanded)
Glioblastoma is one of the most aggressive malignant primary brain cancer in adults. To date, surgery, radiotherapy and current pharmacological treatments are not sufficient to manage this pathology that has a high mortality rate (median survival 12-15 months).